Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Adv Drug Deliv Rev. 2021 Jul 27;176:113896. doi: 10.1016/j.addr.2021.113896

Figure 9.

Figure 9.

FDA IND Pathways. Four potential pathways for new drug products to be expedited during the FDA approval process. These include accelerated approval, fast track designation, breakthrough therapy designation, and priority review. Adapted from ref. [217]. Schematic was made using BioRender.com